Bulletin
Investor Alert

ZIOPHARM Oncology Inc.

NAS: ZIOP

GO
/marketstate/country/us

Market closed

 --Quotes are delayed by 20 min

Nov 18, 2019, 4:00 p.m.

/zigman2/quotes/200291745/composite

$

4.51

Change

+0.06 +1.23%

Volume

Volume 939,302

Quotes are delayed by 20 min

/zigman2/quotes/200291745/composite

Previous close

$ 4.46

$ 4.51

Change

+0.06 +1.23%

Day low

Day high

$4.36

$4.59

Open

52 week low

52 week high

$1.56

$7.25

Open

Annual Financials for ZIOPHARM Oncology Inc.

Operating Activities

Fiscal year is January-December. All values USD millions. 20142015201620172018 5-year trend
Net Income before Extraordinaries (31.78M)(120.09M)(165.3M)(54.32M)(53.12M)
Depreciation, Depletion & Amortization 462,000357,000290,000369,000575,000
Depreciation and Depletion 462,000357,000290,000369,000575,000
Amortization of Intangible Assets -----
Deferred Taxes & Investment Tax Credit -----
Deferred Taxes -----
Investment Tax Credit -----
Other Funds (6.98M)75.28M127.6M9.75M7.38M
Funds from Operations (38.3M)(44.45M)(37.41M)(44.21M)(45.17M)
Extraordinaries -----
Changes in Working Capital 1.65M44.44M(20.92M)(10.46M)(4.29M)
Receivables -(301,000)425,0002,000(1.85M)
Accounts Payable 1.58M4,000(1.85M)4.26M(3.71M)
Other Assets/Liabilities (760,000)43.01M(19.69M)(15.53M)2.41M
Net Operating Cash Flow (36.65M)(10,000)(58.33M)(54.67M)(49.46M)

Investing Activities

20142015201620172018 5-year trend
Capital Expenditures (193,000)(412,000)(551,000)(737,000)(459,000)
Capital Expenditures (Fixed Assets) (193,000)(412,000)(551,000)(737,000)(459,000)
Capital Expenditures (Other Assets) -----
Net Assets from Acquisitions -----
Sale of Fixed Assets & Businesses -----
Purchase/Sale of Investments -----
Purchase of Investments -----
Sale/Maturity of Investments -----
Other Uses -----
Other Sources -----
Net Investing Cash Flow (193,000)(412,000)(551,000)(737,000)(459,000)

Financing Activities

20142015201620172018 5-year trend
Cash Dividends Paid - Total -----
Common Dividends -----
Preferred Dividends -----
Change in Capital Stock 11.44M98.34M(788,000)45.3M45.72M
Repurchase of Common & Preferred Stk. (544,000)(552,000)(1.5M)(2.06M)(1.62M)
Sale of Common & Preferred Stock 11.99M98.89M714,00047.36M47.34M
Proceeds from Stock Options -94.32M-47.27M47.1M
Other Proceeds from Sale of Stock 11.99M4.57M714,00088,000240,000
Issuance/Reduction of Debt, Net -----
Change in Current Debt -----
Change in Long-Term Debt -----
Issuance of Long-Term Debt -----
Reduction in Long-Term Debt -----
Other Funds ----(5.41M)
Other Uses ----(5.41M)
Other Sources -----
Net Financing Cash Flow 11.44M98.34M(788,000)45.3M40.31M
Exchange Rate Effect -----
Miscellaneous Funds -----
Net Change in Cash (25.4M)97.91M(59.66M)(10.11M)(9.61M)
Free Cash Flow (36.84M)(422,000)(58.88M)(55.41M)(49.92M)
Link to MarketWatch's Slice.